SCHEMBL6005502

SCHEMBL6005502

CCOCCOCCNC

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.39
TSHR P16473 1/20 0.37
THRB P10828 1/20 0.37
KDM4E B2RXH2 1/20 0.33
RECQL P46063 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
EPHX1 P07099 1/20 0.32
NPC1 O15118 1/20 0.31
HPGD P15428 1/20 0.31
RAB9A P51151 1/20 0.31
GAA P10253 1/20 0.31
EPHX2 P34913 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15082731 1.00 ALDH1A1 (0.39) ALDH1A1TSHRTHRBKDM4ERECQL
SCHEMBL25922720 1.00 ALDH1A1 (0.39) ALDH1A1TSHRTHRBKDM4ERECQL
SCHEMBL7071314 1.00 ALDH1A1 (0.39) ALDH1A1TSHRTHRBKDM4ERECQL
SCHEMBL19249028 1.00 ALDH1A1 (0.39) ALDH1A1TSHRTHRBKDM4ERECQL
SCHEMBL22269102 1.00 ALDH1A1 (0.39) ALDH1A1TSHRTHRBKDM4ERECQL
SCHEMBL24378505 1.00 ALDH1A1 (0.39) ALDH1A1TSHRTHRBKDM4ERECQL
SCHEMBL126241 0.94
SCHEMBL20075870 0.93 NPC1 (0.35) ALDH1A1TSHRTHRBKDM4EMEN1
SCHEMBL23651532 0.93 KDM4E (0.42) ALDH1A1TSHRTHRBKDM4ERECQL
Hydrochloric Acid SCHEMBL7085471 0.92

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118255787-A Multi-metal oligomer catalyst and method for preparing lactone and lactide homopolymer or copolymer by using same 大连理工大学 2024-06-28 CN claimed
US-20260068886-A1 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL OERTH BIO LLC (US) 2026-03-12 US disclosed
EP-4580405-A1 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL Oerth Bio LLC (US) 2025-07-09 EP disclosed
WO-2024050016-A9 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL OERTH BIO LLC (US) 2025-04-03 WO disclosed
US-20240365736-A1 COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL OERTH BIO LLC (US) 2024-11-07 US disclosed
EP-4395549-A1 COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL Oerth Bio LLC (US) 2024-07-10 EP disclosed
CN-118255787-A Multi-metal oligomer catalyst and method for preparing lactone and lactide homopolymer or copolymer by using same 大连理工大学 2024-06-28 CN disclosed
WO-2024108009-A1 DYRK/CLK PROTACS AND USES THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2024-05-23 WO disclosed
WO-2024050016-A1 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL OERTH BIO LLC (US) 2024-03-07 WO disclosed
US-20230151034-A1 PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION COCRYSTAL PHARMA, INC. 2023-05-18 US disclosed
US-8835625-B2 Propargyl substituted nucleoside compounds and methods APPLIED BIOSYSTEMS, LLC (US) 2014-09-16 US disclosed
US-8835625-B2 Propargyl substituted nucleoside compounds and methods APPLIED BIOSYSTEMS, LLC (US) 2014-09-16 US disclosed
US-20130035635-A1 CARRIER-LINKED CARBAMATE PRODRUG LINKERS ASCENDIS PHARMA A/S (DK) 2013-02-07 US disclosed
US-20120309953-A1 Propargyl Substituted Nucleoside Compounds and Methods Life Technologies Corporation (US) 2012-12-06 US disclosed
US-20120191039-A1 CARRIER LINKED PRAMIPEXOLE PRODRUGS ASCENDIS PHARMA A/S (DK) 2012-07-26 US disclosed
US-20120184489-A1 PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2012-07-19 US disclosed
US-7998706-B2 Pyrimidine nucleobases APPLIED BIOSYSTEMS, LLC (US) 2011-08-16 US disclosed
US-7998706-B2 Pyrimidine nucleobases APPLIED BIOSYSTEMS, LLC (US) 2011-08-16 US disclosed
US-20100113759-A1 PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS Life Technologies Corporation (US) 2010-05-06 US disclosed
US-20060205942-A1 e.g. 2-{2-[545-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-sulthmoyl-biphenyl-3-yl]-acetylsmino}-succinamic; anticoagulant, anticarcinogenic, antiinflammatory agent; deep vein thrombosis, rheumatoid arthritis, stroke PHARMACYCLICS LLC 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151034-A1 PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION ASNS, GLUL, GNMT ALDH1A1 3437/4885TSHR 4157/4885THRB 3327/4885
US-20130035635-A1 CARRIER-LINKED CARBAMATE PRODRUG LINKERS CTSL, SLC16A7, SLC16A8 ALDH1A1 1191/4885TSHR 2746/4885THRB 3226/4885
US-20100113759-A1 PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS PNP, NT5C3B, NUDT1 ALDH1A1 1507/4885TSHR 3709/4885THRB 4298/4885
US-20240365736-A1 COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL CRBN, LTN1, CBL ALDH1A1 4050/4885TSHR 3805/4885THRB 2112/4885
US-20060205942-A1 e.g. 2-{2-[545-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-sulthmoyl-biphenyl-3-yl]-acetylsmino}-succinamic; anticoagulant, anticarcinogenic, antiinflammatory agent; deep vein thrombosis, rheumatoid arthritis, stroke F7, F9, F5 ALDH1A1 1275/4885TSHR 2307/4885THRB 3397/4885
US-20120184489-A1 PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE IAPP, IGF1R, INSR ALDH1A1 468/4885TSHR 721/4885THRB 544/4885
US-20120309953-A1 Propargyl Substituted Nucleoside Compounds and Methods PNP, NUDT1, DUT ALDH1A1 1877/4885TSHR 3080/4885THRB 2862/4885
US-20120191039-A1 CARRIER LINKED PRAMIPEXOLE PRODRUGS PRAP1, LPXN, DNPEP ALDH1A1 2952/4885TSHR 3721/4885THRB 2970/4885
US-20260068886-A1 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL CRBN, STUB1, CUL1 ALDH1A1 3713/4885TSHR 2053/4885THRB 574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.